Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2012
10/23/2012US8293704 Crystalline form of linaclotide
10/23/2012US8293703 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
10/23/2012US8293702 Phenolic binding peptides
10/23/2012US8293700 Anti-bacterial composition especially for controlling gram-negative bacteria, comprising a peptide and an advantageously hydrophobic anti-bacterial agent
10/23/2012US8293528 Peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus
10/23/2012US8293464 Methods for reducing the internalization of viruses and identification of compounds effective thereof
10/23/2012US8293281 Analgesic and anti-inflammatory composition
10/23/2012US8293236 Use of modulators of compounds of TGF-β superfamily to regulate hepcidin-mediated iron metabolism
10/23/2012US8293232 Flowable carrier matrix and methods for delivering to a patient
10/23/2012US8293231 Methods and compositions for treating ischemia
10/23/2012US8293230 Transport protein which is used to introduce chemical compounds into nerve cells
10/23/2012US8293228 Variant form of urate oxidase and use thereof
10/23/2012US8293227 Topical co-enzyme Q10 formulations and methods of use
10/23/2012US8293214 Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds
10/23/2012US8293213 Method and apparatus for thrombus removal using magnetic particles
10/23/2012CA2706634C Preparation of powder agglomerates
10/23/2012CA2522379C The severe acute respiratory syndrome coronavirus
10/23/2012CA2515892C Lipophilic drug delivery vehicle and methods of use thereof
10/23/2012CA2513567C Cop 1 for treatment of inflammatory bowel diseases
10/23/2012CA2488127C Antibodies directed against prothrombin fragment f1+2, the preparation and use thereof
10/23/2012CA2469599C Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
10/23/2012CA2454275C Conformationally constrained parathyroid hormone (pth) analogs
10/23/2012CA2418802C Polypeptide regulating phosphate metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
10/23/2012CA2386141C A novel polypeptide and gene encoding the same
10/23/2012CA2384978C Udp-n-acetylglucosamine: galactose-.beta.1,3-n-acetylgalactosamine-.alpha.-r/(glcnac to galnac) .beta.1,6-n-acetylglucosaminyltransferase, c2gnt3
10/23/2012CA2361009C Her-2/neu fusion proteins
10/23/2012CA2359840C Glycosylated leptin compositions and related methods
10/23/2012CA2334679C Pyrazinone protease inhibitors
10/23/2012CA2284829C Immunotherapy of b-cell malignancies using anti-cd22 antibodies
10/23/2012CA2257839C Gamma-heregulin
10/18/2012WO2012142609A1 Methods for chronic pain management and treatment using hcg
10/18/2012WO2012142604A2 Targeting deregulated wnt signaling in cancer using stabilized alpha-helices of bcl-9
10/18/2012WO2012142526A1 Use of tumor fas expression to determine response to anti-cancer therapy
10/18/2012WO2012142523A2 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
10/18/2012WO2012142434A2 Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
10/18/2012WO2012142410A2 Redox responsive polymeric nanocapsules for protein delivery
10/18/2012WO2012142320A2 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
10/18/2012WO2012142083A2 C1q/tnf-related protein 12 and compositions and methods of using same
10/18/2012WO2012141936A1 Variants of human gdnf
10/18/2012WO2012141795A1 Protein hydrolysate compositions having enhanced cck and glp-1 releasing activity
10/18/2012WO2012141504A2 Brg-1-derived bromodomain, and use thereof
10/18/2012WO2012141316A1 Nutritional composition
10/18/2012WO2012141026A1 Fusion protein
10/18/2012WO2012140376A1 Therapeutic peptides and use thereof against huntington's disease
10/18/2012WO2012140327A1 Method for determining the risk of cardiovascular events using igfbp fragments
10/18/2012WO2012140272A1 Treatment of microbial infections
10/18/2012WO2012140216A1 Pharmaceutical composition
10/18/2012WO2012140155A1 Fatty acid acylated amino acids for oral peptide delivery
10/18/2012WO2012140117A1 Double-acylated glp-1 derivatives
10/18/2012WO2012140082A1 Treatment of hepatitis c virus infection with alisporivir
10/18/2012WO2012139918A1 Methods for treating bacterial infection
10/18/2012WO2012139732A1 Preparation containing disc1 and/or at least one disc1 fragment for use in the therapeutic treatment of the human or animal body
10/18/2012WO2012139519A1 Cyclic peptide and medical use thereof
10/18/2012WO2012139223A1 System and method for multiphasic release of growth factors
10/18/2012WO2012139179A1 Peptides with antimicrobial activity, drug compositions for the prophylaxis and treatment of animals, compositions for the prophylaxis and treatment of plants, uses of said peptides, and uses of paenibacillus elgii ourofinensis extract
10/18/2012WO2012139148A1 Antioxidant composition for tissue and organ preservation
10/18/2012WO2012122519A3 Ligands to the membrane protein caveolin
10/18/2012WO2012122334A3 Procollagen carboxy-terminal propeptides as a target and treatment for angiogenesis related diseases
10/18/2012WO2012108990A3 Peptide-phospholipid conjugates
10/18/2012WO2012095388A3 Compounds for treatment of feline leukemia in felidae
10/18/2012WO2012028526A3 Tetranectin-apolipoprotein a-i, lipid particles containing it and its use
10/18/2012WO2011131360A3 Method of determining the metastatic potential of a tumor
10/18/2012US20120266328 Celluloytic enzymes, nucleic acids encoding them and methods for making and using them
10/18/2012US20120266263 Method of treating memory disorders and enhancing memory using igf-ii compounds
10/18/2012US20120266262 Methods and compositions relating to zpa polypeptides
10/18/2012US20120265712 Methods for Chronic Pain Management and Treatment using HCG
10/18/2012US20120265297 Silk fibroin hydrogels and uses thereof
10/18/2012US20120265129 Methods for Chronic Pain Management and Treatment using HCG
10/18/2012US20120264912 Self-assembling peptide amphiphiles and related methods for growth factor delivery
10/18/2012US20120264834 Disodium salts, monohydrates, and ethanol solvates for delivering active agents
10/18/2012US20120264699 Method of producing autogenous or allogenic blood serum and related logistics
10/18/2012US20120264698 Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions
10/18/2012US20120264697 Uses of hypoxia-inducible factor inhibitors
10/18/2012US20120264696 Prevention of cellular senescence in mammals by natural peptide complexes
10/18/2012US20120264695 Non-porous film for culturing cells
10/18/2012US20120264694 Composition comprising torasemide
10/18/2012US20120264693 Compounds acting as peptide gap junction modulators, and uses thereof
10/18/2012US20120264692 Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
10/18/2012US20120264691 Medical compositions containing ghrelin
10/18/2012US20120264690 Methods of using basic fibroblast growth factor to prevent acute wound failure
10/18/2012US20120264689 Methods and compositions for skin regeneration
10/18/2012US20120264688 Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
10/18/2012US20120264687 Modified erythropoietin to which water-soluble long-chain molecule is added
10/18/2012US20120264686 Modified erythropoietin (epo) polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof
10/18/2012US20120264685 Short chain peptidomimetics based orally active glp 1 agonist and glucagon receptor antagonist
10/18/2012US20120264684 Glycosylated Form of Antigenic GLP-1 Analogue
10/18/2012US20120264683 Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
10/18/2012US20120264682 Tissue protective peptides and uses thereof
10/18/2012US20120264681 Buffered ophthalmic compositions and methods of use thereof
10/18/2012US20120264680 Regulation of energy metabolism and obesity by modulating b cell activating factor (baff, blys) or baff signaling
10/18/2012US20120264679 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
10/18/2012US20120264678 Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
10/18/2012US20120264677 Oxidant resistant apolipoprotein a-1 and mimetic peptides
10/18/2012US20120264676 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
10/18/2012US20120264675 Cmv gene products promote cancer stem cell growth
10/18/2012US20120264674 Methods for preparing purified polypeptide compositions
10/18/2012US20120264168 Zcytor17 heterodimeric cytokine receptor polynucleotides
10/18/2012US20120264143 Cytokine-like proteins
10/18/2012US20120264141 Tuberculosis diagnostic test
10/18/2012US20120263794 Treatment of eye diseases using encapsulated cells encoding and secreting a neuroprotective factor and/or an anti-angiogenic factor
1 ... 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 ... 3163